Reported Consolidated quarterly numbers for Strides Pharma Science are:Net Sales at Rs 864.85 crore in December 2022 up 8.87% from Rs. 794.39 crore in December 2021.
Quarterly Net Loss at Rs. 80.03 crore in December 2022 up 34.23% from Rs. 121.67 crore in December 2021.
EBITDA stands at Rs. 142.54 crore in December 2022 up 1116.21% from Rs. 11.72 crore in December 2021.
| Strides Pharma shares closed at 337.10 on January 23, 2023 (NSE) and has given 0.54% returns over the last 6 months and -10.84% over the last 12 months. |
| Strides Pharma Science | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Dec'22 | Sep'22 | Dec'21 | | Net Sales/Income from operations | 864.85 | 897.10 | 794.39 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 864.85 | 897.10 | 794.39 | | EXPENDITURE | | Consumption of Raw Materials | 307.90 | 372.69 | 317.59 | | Purchase of Traded Goods | 47.66 | 12.31 | 53.91 | | Increase/Decrease in Stocks | 11.94 | 2.10 | 29.60 | | Power & Fuel | -- | -- | -- | | Employees Cost | 181.01 | 191.69 | 179.94 | | Depreciation | 60.22 | 61.70 | 60.90 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 200.00 | 220.19 | 211.82 | | P/L Before Other Inc., Int., Excpt. Items & Tax | 56.12 | 36.43 | -59.37 | | Other Income | 26.20 | 23.46 | 10.19 | | P/L Before Int., Excpt. Items & Tax | 82.32 | 59.89 | -49.18 | | Interest | 58.44 | 67.64 | 42.25 | | P/L Before Exceptional Items & Tax | 23.88 | -7.75 | -91.43 | | Exceptional Items | 41.56 | 14.52 | -15.43 | | P/L Before Tax | 65.44 | 6.77 | -106.86 | | Tax | 4.09 | -38.40 | -4.48 | | P/L After Tax from Ordinary Activities | 61.35 | 45.17 | -102.38 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | 18.57 | -- | | Net Profit/(Loss) For the Period | 61.35 | 63.74 | -102.38 | | Minority Interest | 2.08 | 3.92 | 4.99 | | Share Of P/L Of Associates | -143.45 | -44.84 | -24.28 | | Net P/L After M.I & Associates | -80.03 | 22.83 | -121.67 | | Equity Share Capital | 90.30 | 90.29 | 89.78 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -8.86 | 2.54 | -13.55 | | Diluted EPS | -8.86 | 2.54 | -13.55 | | EPS After Extra Ordinary | | Basic EPS | -8.86 | 2.54 | -13.55 | | Diluted EPS | -8.86 | 2.54 | -13.55 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|